Lurasidone Hydrochloride Tablet, Film Coated
Product Images NDC 13668-509

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lurasidone Hydrochloride (NDC 13668-509). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Torrent Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Chemical Structure)

Chemical structure of lurasidone hydrochloride, a human prescription drug active ingredient shown as a molecular diagram with rings and bonded atoms, including a hydrochloride (HCl) moiety.*

FDA Label Image

Image Description (Container60mg)

Label for Lurasidone Hydrochloride Tablets 60 mg by Torrent Pharmaceuticals Limited. The film-coated oral tablets come in a package of 30 tablets (NDC 13668-509). The label includes storage instructions, manufacturer details (Dr. Reddy's Laboratories Limited), dosage note, and a dispenser attention box advising to provide the Medication Guide with each dispense.*

FDA Label Image

Image Description (Figure1)

A chart titled 'Impact of other drugs on Lurasidone Pharmacokinetics (PK)' showing fold change and 90% confidence intervals. It plots the effects of interacting drugs (Ketoconazole, Diltiazem, Rifampin, Lithium) on Cmax and AUC of lurasidone, with values displayed as changes relative to lurasidone alone on the x-axis. The chart categorizes drugs as strong or moderate CYP3A4 inhibitors or inducers.*

FDA Label Image

Image Description (Figure2)

A forest plot titled 'Impact of Lurasidone Hydrochloride on Other Drugs' showing fold change and 90% confidence intervals for various interacting drugs including P-gp substrates (Digoxin 0.25 mg), CYP3A4 substrates (Midazolam 5 mg), oral contraceptives (Ethinyl Estradiol, Norelgrestromin), and Lithium 600 mg BID. The x-axis represents change relative to the interactive drug alone ranging from -1.0 to 1.0.*

FDA Label Image

Image Description (Figure3)

A pharmacokinetic impact chart showing the fold change and 90% confidence intervals for Lurasidone Hydrochloride related to renal impairment, hepatic impairment, and population factors such as gender and race. The chart compares Cmax and AUC values relative to a reference, illustrating changes across mild, moderate, and severe impairment and demographic subgroups including females and Asians.*

FDA Label Image

Image Description (Logo Pi)

FDA Label Image

Image Description (Logo mg)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.